Clinicopathologic Evaluation of Amyloid Clearance in Alzheimer Disease.

Amyloid clearance after aducanumab treatment is linked to reduced tau pathology and slower cortical atrophy in Alzheimer disease.

• Why it matters: Understanding how amyloid removal influences downstream neuropathology is crucial for evaluating the long-term efficacy of amyloid-targeting therapies in Alzheimer disease.
• What they did: A case report examined a male patient with mild cognitive impairment who received 30 doses of aducanumab over 4.5 years, comparing postmortem and in vivo measures with 14 matched untreated controls.
• The result: Regions with low amyloid levels after treatment showed less tau pathology and slower cortical thinning, especially in gyral crests, suggesting extensive amyloid clearance may be necessary for downstream neuropathologic benefits.